Baird on Sarepta (SRPT): 'we think the regulatory progress can generate incremental optimism around the valuation'
Tweet Send to a Friend
Baird analyst Brian Skorney reiterated an Outperform rating and $200.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).The analyst comments "Incrementally ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
